The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial Infarction

New England Journal of Medicine

Volumn 329, Issue 22, 1993, Pages 1615-1622

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY REPERFUSION; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART VENTRICLE FUNCTION; HEART VENTRICLE PERFORMANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

CINEANGIOGRAPHY; CORONARY ANGIOGRAPHY; CORONARY VESSELS; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HUMAN; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; STREPTOKINASE; SUPPORT, NON-U.S. GOV'T; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY; VENTRICULAR FUNCTION, LEFT;

EID: 0027424433     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199311253292204     Document Type: Article

References (29)

1. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682
2. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71
3. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1993; 339: 753-770
4. Serruys PW, Luijten HE, Beatt KJ, Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon: a quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77: 361-371
5. Chesebro JH, Knatterud G, Roberts R, Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987; 76: 142-154
6. Dodge HT, Sandler H, Ballew DW, Lord JD The use of biplane angiocardiography for the measurement of left ventricular volume in man. Am Heart J 1960; 60: 762-776
7. Bolson EL, Kliman S, Sheehan F, Dodge HT. Left ventricular segmental wall motion -- a new method using local direction information. In: Computers in cardiology. New York: IEEE, 1981:245-8 (microfiche).
8. Conover WJ. Practical nonparametric statistics. 2nd ed. New York: John Wiley, 1980:229.
9. Neter J, Wasserman W, Kutner MH. Applied linear statistical models: regression, analysis of variance, and experimental designs. 2nd ed. Homewood, Ill.: Richard D. Irwin, 1985:950-2.
10. Verstraete M, Bernard R, Bory M, Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: report from the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Lancet 1985; 1: 842-847
11. Neuhaus KL, Feurer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989; 14: 1566-1569
12. Carney R, Brandt T, Daley P, Increased efficacy of rt-PA by more rapid administration: The RAAMI Trial. Circulation 1990; 82: Suppl III: III-538 abstract.
13. Ohman EM, Califf RM, Topol EJ, Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82: 781-791
14. Hsia J, Kleiman N, Aguirre F, Chaitman BR, Roberts R, Ross AM Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency: HART Investigators. J Am Coll Cardiol 1992; 20: 31-35
15. de Bono DP, Simoons ML, Tijssen J, Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122-128
16. Ellis SG, Henschke CI, Sandor T, Wynne J, Braunwald E, Kloner RA Time course of functional and biochemical recovery of myocardium salvaged by reperfusion. J Am Coll Cardiol 1983; 1: 1047-1055
17. Bates ER, Califf RM, Stack RS, Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality. J Am Coll Cardiol 1989; 13: 12-18
18. Morgan CD, Roberts RS, Haq A, Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. J Am Coll Cardiol 1991; 17: 1451-1457
19. Sheehan FH, Braunwald E, Canner P, The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation 1987; 75: 817-829
20. Stack RS, Phillips HR III, Grierson DS, Functional improvement of jeopardized myocardium following intracoronary streptokinase infusion in acute myocardial infarction. J Clin Invest 1983; 72: 84-95
21. Mathey DG, Sheehan FH, Schofer J, Dodge HT Time from onset of symptoms to thrombolytic therapy: a major determinant of myocardial salvage in patients with acute transmural infarction. J Am Coll Cardiol 1985; 6: 518-525
22. Davies GJ, Chierchia S, Maseri A Prevention of myocardial infarction by very early treatment with intracoronary streptokinase: some clinical observations. N Engl J Med 1984; 311: 1488-1492
23. Belenkie I, Thompson CR, Manyari DE, Importance of effective, early and sustained reperfusion during acute myocardial infarction. Am J Cardiol 1989; 63: 912-916
24. Koren G, Weiss AT, Hasin Y, Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. N Engl J Med 1985; 313: 1384-1389
25. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402
26. Van de Werf F Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet 1989; 1: 1367-1369
27. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21: 1391-1395
28. Karagounis L, Sorensen SG, Menlove RL, Moreno F, Anderson JL Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol 1992; 17: 1-10
29. Schmidt SB, Varghese PJ, Bloom S, Yackee JM, Ross AM The influence of residual coronary stenosis on size of infarction after reperfusion in a canine preparation. Circulation 1986; 73: 1354-1359